A controlled substance is a drug or medication that is labeled as illicit due to its addictive nature. The government restricts its manufacture, use, and possession. Such medications can only be acquired through a doctor’s prescription that too when is considered extremely necessary.
Because of Soma’s potential for abuse, Soma is a controlled substance in 18 U.S. states:
- New Mexico
- West Virginia
The U.S. drug enforcement agency listed Soma as a drug of concern and is conducting hearings to determine whether it should be classified at the federal level as a control substance.
Is Soma a Schedule 1 drug?
In December 2011, the Drug Enforcement Agency decided to control the drug as a Schedule I controlled substance under the Controlled Substances Act (C.S.A.). The D.E.A. (Drug Enforcement Agency) published a final rule (76 FR 77330) in the federal register that makes carisoprodol a Class I controlled substance.
Later on January 11, 2012, the D.E.A. (Drug Enforcement Agency) classified carisoprodol as a schedule IV controlled substance at the federal level. The final rule is that as of January 11, 2012, all prescription drugs containing carisoprodol must comply with 21 C.F.R. SS 130604. The medicines must also contain the information required under 21CFR.
Schedule I drugs consist of medications or substances guaranteed to cause extreme addiction and pose a high risk of abuse.
What kind of drug is Carisoprodol?
Carisoprodol is a muscle relaxant that blocks pain sensations in the nerves of the brain. It is often used in resting and physiotherapy to treat skeletal muscles such as pain and injury. It is also used for recovery, physical therapy, and other measures to relax muscle strains and sprained muscle injuries.
Carisoprodol is the most active and prominent substance present in Soma. Carisoprodol subject is to abuse, dependence, withdrawal, abuse, and criminal diversion. As Soma induces a calming effect, other C.N.S. depressants like alcohol, benzodiazepines, opioids, and tricyclic antidepressants may be additives.
Is Carisoprodol 350 mg a Narcotic?
The typical 350 mg dose is unlikely to cause any prominent side effects except drowsiness, mild to significant euphoria, and dysphoria, but these effects are short-lived due to the rapid metabolism of carisoprodol with meprobamate and other metabolites and are largely due to its inherent anxiolytic solid effect, strong enough to produce its primary metabolite meprobamate, which is falsely blamed for the intense effects of the metabolite.
Although Soma is not a narcotic such as opioids, benzodiazepines, or barbiturates as a controlled substance, it can be used with these drugs in combination to enhance its effect with significant negative effects. That means you can buy somas online or from nearest pharmacy with prescription.
The overconsumption of carisoprodol and other medications will make you drowsy or decrease your breathing rate and can cause severe side effects, which could even lead to death. Some medications may affect your blood level or other medications you take, which may exacerbate side effects or make the medication less effective.
Suddenly halting the use of carisoprodol will make you experience severe withdrawal symptoms like insomnia, vomiting, abdominal pain, headaches, tremors, twitching, ataxia, hallucinations, and psychosis.
Does Carisoprodol make you high?
Yes, Carisoprodol can get you high, but the effects won’t be severe as Soma does not fall in the narcotics category of medications.
When utilized for the treatment of musculoskeletal pain will give a brief euphoric phase while taking effect to relieve muscle tension. The intensity of its speedy action provides users a high, euphoric feeling known as a soma-high feeling. Due to its toxic effects, doctors usually prescribe carisoprodol for up to three weeks.
Misuse of the drug carries the risk of overdose, leading to death due to C.N.S. depression (respiratory diseases), hypotension, seizures, and other overdose disorders.
Yan Li, Chris Delcher, Joshua D. Brown, Yu-Jung Wei, Gary M. Reisfield, Almut G. Winterstein, Impact of Schedule IV controlled substance classification on carisoprodol utilization in the United States: An interrupted time series analysis,
Drug and Alcohol Dependence,https://www.sciencedirect.com/science/article/pii/S0376871619302522